Alunbrig (brigatinib) is available from Onco360!
ALUNBRIG® is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Dosage and Administration
The recommended dosage for ALUNBRIG is 90 mg orally once daily for the first 7 days; then increase to 180 mg orally once daily. May be taken with or without food.
Dosage Forms and Strengths
For more information, visit Alunbrig.com
How to Refer
Oncomed Dba Onco360 or